Our Technology

We are developing an innovative Nanobody® therapy designed to target and inhibit Nogo-A, a key protein that restricts brain repair and recovery.
Delivered intranasally, our Nanobody® bypasses the blood-brain barrier, ensuring effective drug delivery directly to the brain.
This regenerative therapy enhances the brain’s natural ability to regrow axons and restore synaptic connections, promoting long-term healing.
By boosting neuroplasticity, our treatment aims to help patients recover faster and achieve greater functional improvements in their recovery.

Nogo-A inhibits brain repair, blocking the formation of new neural connections.
This slows recovery from TBI, CTE, stroke, and other brain injuries, limiting functional improvement.
Many patients face long-term or permanent impairments, even with the best treatments.
Blocking Nogo-A has been shown to enhance neuroplasticity, accelerate recovery, and improve outcomes in preclinical models. (1)

Targets & blocks Nogo-A, removing barriers to brain repair and regeneration.
Promotes axonal regrowth and enhances neuroplasticity, supporting faster and more effective recovery.
Designed for TBI, CTE, stroke, and other brain injuries, aiming to restore function and improve outcomes.
Why Nanobodies?:
Smaller & more stable than traditional antibodies, allowing deeper tissue penetration.
Higher specificity & binding affinity, maximizing therapeutic effectiveness.
Easier & more cost-effective to manufacture, enabling broader accessibility.

Bypasses the blood-brain barrier, delivering drugs directly to the brain for faster and more effective treatment.
More efficient drug delivery, ensuring a higher concentration reaches the target site with minimal loss.
Non-invasive & patient-friendly, eliminating the need for injections or invasive procedures.
Reduces systemic side effects, avoiding complications associated with traditional drug delivery methods.
Improves patient access & compliance, making treatment more practical and widely accessible.